From USFDA
Cadila Healthcare announced that the Company's Topical manufacturing facility located at Changodar, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in March 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised. The topical plant is a dedicated facility for manufacturing ointments and does not form a part of the Moraiya formulations manufacturing plant.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
